← ANALYST RATINGS · TIPRANKS
AgomAb Therapeutics NV ADR (AGMB): analyst forecast and price target
Analyst consensus
Strong Buy3 Buy0 Hold0 Sell
Ratings of 3 analysts in the last 3 months · top analysts only12-month forecast
Based on 3 price targets given in the last 3 months, the average target is $47.50, the highest $60.00, the lowest $35.00. The average is +473.7% from the last price of $8.28.
Analyst ratings 12
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| Yasmeen Rahimi★★★★★★★★★★#160 · hits 51% · avg +36.0% | Piper Sandler | $60.00 | Buy | +624.6% | Reiterated | 14.10.26on TipRanks 07:25 | −0.3%next day −4.4% | ↗ |
| Judah Frommer★★★★★★★★★★#2495 · hits 56% · avg +5.3% | Morgan Stanley | $28.00 | Buy | +238.2% | Reiterated | 12.10.26on TipRanks 08:20 | +0.2%next day −3.1% | ↗ |
| Judah Frommer★★★★★★★★★★#2495 · hits 56% · avg +5.3% | Morgan Stanley | $28.00 | Buy | +238.2% | Assigned | 05.10.26on TipRanks 08:35 | +0.8%next day +1.2% · 5 days +4.2% | ↗ |
| Yasmeen Rahimi★★★★★★★★★★#160 · hits 51% · avg +36.0% | Piper Sandler | $60.00 | Buy | +624.6% | Reiterated | 05.10.26on TipRanks 07:56 | +0.8%next day +1.2% · 5 days +4.2% | ↗ |
| Unknown Analyst | Leerink Partners | $36.00 | Buy | +334.8% | Reiterated | 02.10.26on TipRanks 08:30 | −1.8%next day +0.8% · 5 days +4.9% | ↗ |
| Patrick Trucchio★★★★★★★★★★#79 · hits 58% · avg +37.9% | H.C. Wainwright | $35.00 | Buy | +322.7% | Reiterated | 01.10.26on TipRanks 08:50 | −22.3%next day −1.8% · 5 days +5.3% | ↗ |
| Judah Frommer★★★★★★★★★★#2495 · hits 56% · avg +5.3% | Morgan Stanley | $28.00 | Buy | +238.2% | Assigned | 28.09.26on TipRanks 08:20 | −2.1%next day +3.3% · 5 days −16.1% | ↗ |
| Yasmeen Rahimi★★★★★★★★★★#160 · hits 51% · avg +36.0% | Piper Sandler | $60.00 | Buy | +624.6% | Reiterated | 15.09.26on TipRanks 07:30 | −0.5%next day −5.7% · 5 days −7.9% | ↗ |
| Anupam Rama★★★★★★★★★★#291 · hits 54% · avg +23.3% | J.P. Morgan | — | Buy | — | Reiterated | 14.09.26on TipRanks Sep 15 07:55 | −5.5%next day −0.5% · 5 days −6.6% | ↗ |
| Yanni Souroutzidis★★★★★★★★★★#10612 · hits 25% · avg −16.7% | Cantor Fitzgerald | $13.00 → $17.00+30.8% | Buy | +105.3% | Initiated | 19.08.26on TipRanks 06:21 | −0.1%next day −1.5% · 5 days +4.2% | ↗ |
| William Wood★★★★★★★★★★#3198 · hits 53% · avg +11.7% | B. Riley Securities | $34.00 | Buy | +310.6% | Initiated | 23.07.26on TipRanks 21:36 | −3.6%next day 0.0% · 5 days +1.8% | ↗ |
| Thomas Smith★★★★★★★★★★#45 · hits 57% · avg +51.1% | Leerink Partners | $36.00 | Buy | +334.8% | Initiated | 03.03.26on TipRanks Mar 5 05:00 | −1.0%next day −8.4% · 5 days −13.1% | ↗ |
| No ratings for this filter. | ||||||||
Every rating the collector has kept for the last 12 months, including the earlier ones of the same analyst. Latest of each analyst
Best analysts covering AgomAb Therapeutics NV ADR
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $34.80 at a price of $11.10 (+213.5%); now: $35.00 at $8.28 (+322.7%).
PriceAverage targetTop analysts’ target
Recommendation trend · top analysts
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 1 | 2 | 4 | 6 | 8 |
| Buy | 0 | 0 | 0 | 0 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Best top-analyst consensus in the sector · Healthcare
About AgomAb Therapeutics NV ADR
- CEO: Tim Knotnerus
- Employees: 62
- Posthoflei 1/6, Antwerp, VL, 2600, BE
- agomab.com
AgomAb Therapeutics N.V. is a clinical-stage biopharmaceutical company dedicated to developing novel, disease-modifying therapies. Its primary focus lies in immunology and inflammatory ailments, particularly chronic fibrotic conditions where significant unmet medical needs persist. Its innovative pipeline features several promising candidates, including Ontunisertib (AGMB-129), an orally administered, gastrointestinal-restricted small molecule inhibitor targeting ALK5 or TGFßR1, designed to treat Fibrostenosing Crohn's disease and presently undergoing Phase 2a clinical trials. Also in development is AGMB-447, an inhaled small molecule that similarly inhibits ALK5 or TGFßR1, intended for idiopathic pulmonary fibrosis and currently in Phase 1 clinical studies. Furthermore, the company is advancing AGMB-101, a monoclonal antibody designed to mimic HGF. This agent exerts its effects through the agonism or stimulation of the MET receptor, having demonstrated both antifibrotic and regenerative capabilities in preclinical models. Established in 2017, AgomAb Therapeutics maintains its headquarters in Antwerp, Belgium.
Data from the stock’s TipRanks forecast page, read 31 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗